Uniunea Europeană - română - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Uniunea Europeană - română - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun pharmaceuticals s.a. - romania - combinatii - sol. perf. - solutii pentru administrare intravenoasa solutii implicate in balanta hidroelectrolitica (b05xa)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

siegfried hameln gmbh - germania - dobutaminum - sol. perf. - 5mg/ml - stimulante cardiace excl. glicozizi cardiotonici med.adrenergice si dopaminergice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

farmex company s.r.l. - romania - piracetam - compr. - 400mg - psihostimulante, med. utilizate in adhd si nootrope alte psihostimulante si nootrope

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gedeon richter romania s.a. - romania - lorazepamum - compr. - 1 mg - anxiolitice benzodiazepine si derivati

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

vifor france sa - franta - complex de hidroxid de plantaȚii (iii) sucroza - sol. inj./perf. - 100mg/5 ml - preparate cu fer fer trivalent,preparate parenterale

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintofarm s.a. - romania - piracetam - compr. - 400mg - psihostimulante, med. utilizate in adhd si nootrope alte psihostimulante si nootrope

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

u.c.b. pharma s.a. - belgia - piracetam - compr. film. - 800mg - psihostimulante, med. utilizate in adhd si nootrope alte psihostimulante si nootrope

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

b. braun melsungen ag - germania - hidroxietil - amidon - sol. perf. - 6g/100ml - singe si substituenti de singe substituenti de singe si fractiuni proteice plasmatice